Sep 2026· Expert Review of Neurotherapeutics· Vol 26, pp. 923 - 941· 0 citations· 116 references
Medicine
TL;DR
YOAD remains underrecognized and diagnostically challenging, limiting timely access to targeted therapies and the integration of multimodal biomarkers and genetic testing is essential for early diagnosis, as is the need for a comprehensive neuropsychological assessment to capture atypical phenotypes.
Abstract
ABSTRACT Introduction Young-onset Alzheimer’s disease (YOAD), defined by symptom onset before 65 years, represents a distinct subtype of Alzheimer’s disease with important diagnostic and therapeutic implications. Compared with late-onset Alzheimer’s disease (LOAD), YOAD shows greater phenotypic heterogeneity, more frequent atypical non-amnestic presentations, and a stronger genetic contribution, leading to a delay in diagnosis and a substantial psychosocial burden. Areas covered This review summarizes the current evidence on epidemiology, genetics, clinical phenotypes, and diagnostic strategies. YOAD differs from LOAD in terms of broader differential diagnoses and atypical cognitive syndromes. Advances in biomarker-based diagnostics, neuroimaging, and blood-based markers, are discussed, with an emphasis on early detection, patient stratification, and relevance for emerging disease-modifying therapies. A systematic PubMed literature search covering the years 2010 to 2026, used search terms related to YOAD, clinical phenotypes, biomarkers, neuroimaging, and genetic factors. Expert opinion YOAD remains underrecognized and diagnostically challenging, limiting timely access to targeted therapies. The integration of multimodal biomarkers and genetic testing is essential for early diagnosis, as is the need for a comprehensive neuropsychological assessment to capture atypical phenotypes. Future neurotherapeutic strategies also require age-specific approaches and the adaptation of health care systems to address the distinct clinical and socioeconomic needs in YOAD.
Introduction: Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 60–80% of cases, and its prevalence is increasing as the population ages. It is estimated that approximately 50 million people worldwide currently live with dementia, and this number could triple by 2050. AD is a chronic, progre...
Mateusz Cieciora, M. Kawiorska, Julia Surowiec et al.· International Journal of Inn...· 0 citations
Background. Young-onset Parkinsonʼs disease (YOPD) is considered a clinically and genetically heterogeneous form of neurodegenerative pathology characterized by disease onset before the age of 50 years. Despite lower prevalence compared with classical Parkinsonʼs disease, YOPD is associated with substantial medical and...
I. Chernenko, Roman Chernenko· Psychiatry Neurology and Med...· 0 citations
It is argued that government policies must integrate psychologists into multidisciplinary neurological and geriatric teams, and that psychology training programs must be updated to prepare professionals for preventive roles.
Maria Tereza Mendes Aversi, P. M. Freitas, T. Aversi-Ferreira· Frontiers in Psychology· 0 citations
Neuroimaging is now a cornerstone of Alzheimer's disease care and a crucial discriminator tool for characterising brain injury across the lifespan and with emerging fluid biomarkers, neuroimaging supports accurate diagnosis, prognosis, and treatment monitoring.
Tammie L. S. Benzinger, P. Cogswell, A. Arani et al.· Lancet Neurology· 2 citations
Introduction Early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease (LOAD) may differ in large-scale network organization. We compared multimodal MRI markers of diagnosis-age-defined Alzheimer’s phenotypes. Methods Alzheimer’s Disease Neuroimaging Initiative participants were classified by age at fir...
Ze-Song Yuan, Jing Wang, Bao-Hua Cheng et al.· Frontiers in Neuroscience· 0 citations
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...
Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al.· Bioanalysis· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.